STOCK TITAN

[424B2] Inverse VIX Short-Term Futures ETNs due March 22, 2045 Prospectus Supplement

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

UBS AG London Branch is offering $710,000 principal amount of Trigger Autocallable Contingent Yield Notes linked to the common stock of UnitedHealth Group Inc. (UNH), maturing on 13 July 2028. Each $1,000 note pays a 13.85% p.a. quarterly contingent coupon ($34.625 per period) only when UNH’s closing price on an observation date is at or above the Coupon Barrier / Downside Threshold of $179.71 (60 % of the $299.51 initial level).

Beginning six months after issuance, the notes will be automatically called if UNH closes at or above the Call Threshold ($299.51, 100 % of the initial level) on any quarterly observation date. Early redemption pays principal plus the due coupon and terminates the investment.

If not called, the maturity payoff depends on the final level:

  • ≥ $179.71 (≥ 60 %): return of principal (and final coupon, if barrier met).
  • < $179.71: investors receive $1,000 × (1 + Underlying Return), incurring the full percentage loss of UNH below the initial level, down to a total loss of principal.
All payments are general unsecured obligations of UBS AG; coupon and principal protection are contingent.

Key economic terms:

  • Issue price: $1,000; estimated initial value: $970 (reflects dealer spread, funding & hedging costs).
  • Underwriting discount: $23.50 (2.35 %) per note; net proceeds to UBS: $976.50.
  • Trade date: 10 Jul 2025; settlement: 15 Jul 2025; quarterly observation dates; first potential call settlement: 15 Jan 2026.
  • Notes will not be listed; UBS Securities LLC intends—but is not required—to provide secondary markets.

Primary risks include:

  • Loss of up to 100 % of principal if UNH falls >40 % at final valuation.
  • No coupons if UNH stays below the 60 % barrier on observation dates.
  • Credit exposure to UBS AG; payments depend on issuer solvency.
  • Estimated value below issue price and potentially wide bid/ask spreads.
  • Limited liquidity; investors may need to hold to maturity or accept a discount.

The notes may appeal to investors seeking high contingent income and willing to accept equity-like downside and issuer credit risk, forfeiting any upside beyond coupons and facing possible early redemption.

UBS AG Filiale di Londra offre un ammontare principale di $710.000 di Trigger Autocallable Contingent Yield Notes collegati alle azioni ordinarie di UnitedHealth Group Inc. (UNH), con scadenza il 13 luglio 2028. Ogni nota da $1.000 paga un coupon trimestrale contingente del 13,85% annuo ($34,625 per periodo) solo se il prezzo di chiusura di UNH in una data di osservazione è pari o superiore alla Barriera del Coupon / Soglia di ribasso di $179,71 (60% del livello iniziale di $299,51).

A partire da sei mesi dopo l’emissione, le note saranno richiamate automaticamente se UNH chiude pari o superiore alla Soglia di Richiamo ($299,51, 100% del livello iniziale) in una qualsiasi data di osservazione trimestrale. Il rimborso anticipato prevede il pagamento del capitale più il coupon dovuto e termina l’investimento.

Se non richiamate, il pagamento a scadenza dipende dal livello finale:

  • ≥ $179,71 (≥ 60%): restituzione del capitale (e ultimo coupon, se barriera rispettata).
  • < $179,71: gli investitori ricevono $1.000 × (1 + Rendimento Sottostante), subendo la perdita percentuale completa di UNH sotto il livello iniziale, fino alla perdita totale del capitale.
Tutti i pagamenti sono obbligazioni generali non garantite di UBS AG; coupon e protezione del capitale sono condizionati.

Termini economici chiave:

  • Prezzo di emissione: $1.000; valore iniziale stimato: $970 (riflette spread del dealer, costi di finanziamento e copertura).
  • Sconto di sottoscrizione: $23,50 (2,35%) per nota; proventi netti per UBS: $976,50.
  • Data di negoziazione: 10 lug 2025; regolamento: 15 lug 2025; date di osservazione trimestrali; primo possibile regolamento di richiamo: 15 gen 2026.
  • Le note non saranno quotate; UBS Securities LLC intende – ma non è obbligata – a fornire mercati secondari.

Rischi principali includono:

  • Perdita fino al 100% del capitale se UNH scende oltre il 40% alla valutazione finale.
  • Nessun coupon se UNH resta sotto la barriera del 60% nelle date di osservazione.
  • Esposizione creditizia a UBS AG; i pagamenti dipendono dalla solvibilità dell’emittente.
  • Valore stimato inferiore al prezzo di emissione e potenziali ampi spread denaro-lettera.
  • Liquidità limitata; gli investitori potrebbero dover mantenere fino a scadenza o accettare uno sconto.

Le note possono interessare investitori in cerca di un elevato reddito contingente disposti ad accettare un rischio di ribasso simile a quello azionario e il rischio di credito dell’emittente, rinunciando a qualsiasi rialzo oltre i coupon e affrontando la possibile richiamata anticipata.

UBS AG Sucursal de Londres ofrece un monto principal de $710,000 en Trigger Autocallable Contingent Yield Notes vinculados a las acciones ordinarias de UnitedHealth Group Inc. (UNH), con vencimiento el 13 de julio de 2028. Cada nota de $1,000 paga un cupón trimestral contingente del 13.85% anual ($34.625 por período) solo cuando el precio de cierre de UNH en una fecha de observación está en o por encima de la Barrera de Cupón / Umbral de Caída de $179.71 (60% del nivel inicial de $299.51).

A partir de seis meses después de la emisión, las notas serán llamadas automáticamente si UNH cierra en o por encima del Umbral de Llamado ($299.51, 100% del nivel inicial) en cualquier fecha de observación trimestral. El rescate anticipado paga el principal más el cupón correspondiente y termina la inversión.

Si no se llaman, el pago al vencimiento depende del nivel final:

  • ≥ $179.71 (≥ 60%): devolución del principal (y cupón final, si se cumple la barrera).
  • < $179.71: los inversores reciben $1,000 × (1 + Rendimiento Subyacente), asumiendo la pérdida porcentual total de UNH por debajo del nivel inicial, hasta una pérdida total del principal.
Todos los pagos son obligaciones generales no garantizadas de UBS AG; el cupón y la protección del principal son condicionales.

Términos económicos clave:

  • Precio de emisión: $1,000; valor inicial estimado: $970 (refleja spread del distribuidor, costos de financiamiento y cobertura).
  • Descuento de suscripción: $23.50 (2.35%) por nota; ingresos netos para UBS: $976.50.
  • Fecha de negociación: 10 jul 2025; liquidación: 15 jul 2025; fechas de observación trimestrales; primer posible pago por llamado: 15 ene 2026.
  • Las notas no estarán listadas; UBS Securities LLC tiene la intención —pero no está obligado— de proporcionar mercados secundarios.

Riesgos principales incluyen:

  • Pérdida de hasta el 100% del principal si UNH cae más del 40% en la valoración final.
  • No hay cupones si UNH permanece por debajo de la barrera del 60% en las fechas de observación.
  • Exposición crediticia a UBS AG; los pagos dependen de la solvencia del emisor.
  • Valor estimado por debajo del precio de emisión y posibles amplios spreads de compra/venta.
  • Liquidez limitada; los inversores pueden necesitar mantener hasta el vencimiento o aceptar un descuento.

Las notas pueden atraer a inversores que buscan altos ingresos contingentes y están dispuestos a aceptar un riesgo a la baja similar al de acciones y riesgo crediticio del emisor, renunciando a cualquier ganancia más allá de los cupones y enfrentando posible rescate anticipado.

UBS AG 런던 지점UnitedHealth Group Inc. (UNH)의 보통주에 연계된 Trigger Autocallable Contingent Yield Notes 원금 $710,000을 제공하며, 만기는 2028년 7월 13일입니다. 각 $1,000 노트는 UNH의 종가가 관측일에 쿠폰 장벽/하락 한계 $179.71 (초기 수준 $299.51의 60%) 이상일 때만 분기별로 연 13.85%의 조건부 쿠폰(기간당 $34.625)을 지급합니다.

발행 6개월 후부터는 UNH가 분기별 관측일에 콜 임계값($299.51, 초기 수준의 100%) 이상으로 마감하면 노트가 자동으로 상환됩니다. 조기 상환 시 원금과 해당 쿠폰이 지급되며 투자는 종료됩니다.

콜되지 않을 경우 만기 지급액은 최종 수준에 따라 달라집니다:

  • ≥ $179.71 (≥ 60%): 원금 반환(장벽 충족 시 최종 쿠폰 포함).
  • < $179.71: 투자자는 $1,000 × (1 + 기초자산 수익률)를 받으며, 초기 수준 이하 UNH의 하락률만큼 전액 손실을 입을 수 있습니다.
모든 지급은 UBS AG의 일반 무담보 채무이며, 쿠폰과 원금 보호는 조건부입니다.

주요 경제 조건:

  • 발행가: $1,000; 추정 초기 가치: $970 (딜러 스프레드, 자금 조달 및 헤지 비용 반영).
  • 인수 할인: 노트당 $23.50 (2.35%); UBS 순수익: $976.50.
  • 거래일: 2025년 7월 10일; 결제일: 2025년 7월 15일; 분기별 관측일; 첫 조기 상환 가능 결제일: 2026년 1월 15일.
  • 노트는 상장되지 않음; UBS Securities LLC는 2차 시장 제공을 계획하지만 의무는 아님.

주요 위험은 다음과 같습니다:

  • UNH가 최종 평가 시 40% 이상 하락하면 원금 최대 100% 손실 가능.
  • 관측일에 UNH가 60% 장벽 아래에 있으면 쿠폰 미지급.
  • UBS AG에 대한 신용 노출; 지급은 발행자의 지급 능력에 달려 있음.
  • 발행가보다 낮은 추정 가치 및 넓은 매수/매도 스프레드 가능성.
  • 유동성 제한; 투자자는 만기까지 보유하거나 할인된 가격에 매도할 수 있음.

이 노트는 높은 조건부 수익을 추구하며 주식과 유사한 하방 위험과 발행자 신용 위험을 감수할 투자자에게 적합하며, 쿠폰 이상의 상승 이익을 포기하고 조기 상환 가능성에 직면할 수 있습니다.

UBS AG Succursale de Londres propose un montant principal de 710 000 $ en Trigger Autocallable Contingent Yield Notes liés aux actions ordinaires de UnitedHealth Group Inc. (UNH), arrivant à échéance le 13 juillet 2028. Chaque note de 1 000 $ verse un coupon trimestriel conditionnel de 13,85 % par an (34,625 $ par période) uniquement lorsque le cours de clôture de UNH à une date d’observation est égal ou supérieur à la barrière de coupon / seuil de baisse de 179,71 $ (60 % du niveau initial de 299,51 $).

À partir de six mois après l’émission, les notes seront appelées automatiquement si UNH clôture à ou au-dessus du seuil d’appel (299,51 $, 100 % du niveau initial) à une date d’observation trimestrielle. Le remboursement anticipé paie le principal plus le coupon dû et met fin à l’investissement.

Si elles ne sont pas appelées, le paiement à l’échéance dépend du niveau final :

  • ≥ 179,71 $ (≥ 60 %) : remboursement du principal (et coupon final si la barrière est atteinte).
  • < 179,71 $ : les investisseurs reçoivent 1 000 $ × (1 + rendement sous-jacent), subissant la perte en pourcentage complète de UNH sous le niveau initial, jusqu’à une perte totale du principal.
Tous les paiements sont des obligations générales non garanties de UBS AG ; le coupon et la protection du principal sont conditionnels.

Principaux termes économiques :

  • Prix d’émission : 1 000 $ ; valeur initiale estimée : 970 $ (intègre le spread du teneur de marché, les coûts de financement et de couverture).
  • Remise de souscription : 23,50 $ (2,35 %) par note ; produit net pour UBS : 976,50 $.
  • Date de transaction : 10 juillet 2025 ; règlement : 15 juillet 2025 ; dates d’observation trimestrielles ; premier règlement possible d’appel : 15 janvier 2026.
  • Les notes ne seront pas cotées ; UBS Securities LLC prévoit — mais n’est pas obligée — de fournir des marchés secondaires.

Principaux risques incluent :

  • Perte pouvant atteindre 100 % du principal si UNH chute de plus de 40 % à la valorisation finale.
  • Pas de coupons si UNH reste sous la barrière de 60 % aux dates d’observation.
  • Exposition au risque de crédit de UBS AG ; les paiements dépendent de la solvabilité de l’émetteur.
  • Valeur estimée inférieure au prix d’émission et spreads acheteur/vendeur potentiellement larges.
  • Liquidité limitée ; les investisseurs peuvent devoir conserver jusqu’à l’échéance ou accepter une décote.

Ces notes peuvent intéresser les investisseurs recherchant un revenu conditionnel élevé et prêts à accepter un risque de baisse similaire à celui des actions ainsi que le risque de crédit de l’émetteur, renonçant à tout potentiel de hausse au-delà des coupons et faisant face à un possible remboursement anticipé.

UBS AG London Niederlassung bietet eine Hauptsumme von $710.000 in Trigger Autocallable Contingent Yield Notes an, die an die Stammaktien von UnitedHealth Group Inc. (UNH) gekoppelt sind und am 13. Juli 2028 fällig werden. Jede $1.000 Note zahlt einen vierteljährlichen bedingten Kupon von 13,85% p.a. ($34,625 pro Periode), jedoch nur, wenn der Schlusskurs von UNH am Beobachtungstag auf oder über der Kupon-Schwelle / Downside-Schwelle von $179,71 (60 % des Anfangsniveaus von $299,51) liegt.

Ab sechs Monaten nach Ausgabe werden die Notes automatisch zurückgerufen, wenn UNH an einem vierteljährlichen Beobachtungstag auf oder über der Rückruf-Schwelle ($299,51, 100 % des Anfangsniveaus) schließt. Eine vorzeitige Rückzahlung zahlt den Kapitalbetrag plus den fälligen Kupon und beendet die Anlage.

Wird nicht zurückgerufen, hängt die Rückzahlung bei Fälligkeit vom Endniveau ab:

  • ≥ $179,71 (≥ 60 %): Rückzahlung des Kapitals (und finaler Kupon, falls Schwelle erfüllt).
  • < $179,71: Anleger erhalten $1.000 × (1 + Basisrendite), erleiden also den vollen prozentualen Verlust von UNH unter dem Anfangsniveau bis hin zum Totalverlust des Kapitals.
Alle Zahlungen sind unbesicherte allgemeine Verbindlichkeiten der UBS AG; Kupon und Kapitalschutz sind bedingt.

Wichtige wirtschaftliche Bedingungen:

  • Ausgabepreis: $1.000; geschätzter Anfangswert: $970 (berücksichtigt Händler-Spread, Finanzierung & Absicherungskosten).
  • Underwriting-Discount: $23,50 (2,35 %) pro Note; Nettoerlös für UBS: $976,50.
  • Handelstag: 10. Juli 2025; Abwicklung: 15. Juli 2025; vierteljährliche Beobachtungstermine; erster möglicher Rückzahlungszeitpunkt: 15. Januar 2026.
  • Die Notes werden nicht börsennotiert; UBS Securities LLC beabsichtigt – ist aber nicht verpflichtet – Sekundärmärkte bereitzustellen.

Hauptrisiken umfassen:

  • Verlust von bis zu 100 % des Kapitals, wenn UNH bei der Endbewertung um mehr als 40 % fällt.
  • Keine Kupons, wenn UNH an Beobachtungstagen unter der 60 %-Schwelle bleibt.
  • Kreditrisiko gegenüber UBS AG; Zahlungen hängen von der Solvenz des Emittenten ab.
  • Geschätzter Wert unter dem Ausgabepreis und potenziell breite Geld-/Briefspannen.
  • Begrenzte Liquidität; Anleger müssen möglicherweise bis zur Fälligkeit halten oder Abschläge akzeptieren.

Die Notes könnten für Anleger attraktiv sein, die ein hohes bedingtes Einkommen suchen und bereit sind, ein aktienähnliches Abwärtsrisiko sowie Emittenten-Kreditrisiko zu akzeptieren, dabei auf Kursgewinne über die Kupons hinaus verzichten und eine mögliche vorzeitige Rückzahlung in Kauf nehmen.

Positive
  • High contingent coupon: 13.85 % p.a. offers sizable income relative to prevailing rates.
  • 40 % downside buffer: principal is fully protected at maturity as long as UNH does not fall more than 40 %.
  • Quarterly automatic call: potential early exit with full principal and coupon if UNH closes ≥ 100 % of initial level.
Negative
  • Full downside participation below 60 %: investors suffer 1-for-1 losses if UNH declines more than 40 % at final valuation.
  • Credit risk of UBS AG: payments depend on the issuer’s solvency; Swiss bail-in regime could impose losses.
  • Limited upside: returns capped at coupon; no participation in UNH appreciation.
  • Illiquidity: notes are unlisted; secondary market, if any, may trade at significant discount.
  • Issue premium: Estimated initial value is $970 vs. $1,000 issue price, embedding fees and hedging costs.

Insights

TL;DR: 13.85% coupon and 40 % buffer are attractive, but investors bear full UNH downside, UBS credit risk and poor liquidity.

Analysis: The notes embed a digital income stream (knock-in/knock-out) with a call strike at par. A 60 % barrier provides moderate downside protection relative to recent UNH volatility (~22 % 1-yr). The generous 13.85 % coupon compensates for:
• 2.35 % upfront friction and a 3 % theoretical OAS versus par.
• Illiquidity and potential discount trading (initial fair value 97 % of par).
• 40 % first-loss tranche on UNH at maturity.
UBS senior unsecured debt trades near SOFR + 85 bp; thus issuer credit is investment-grade but not risk-free. The automatic call at 100 % limits duration and total return if UNH stays flat or rallies. Overall, the structure suits tactical income buyers with a constructive but not bullish view on UNH and acceptance of principal risk.

TL;DR: Product shifts UNH equity risk and UBS credit spread to retail investors; negative on risk-adjusted basis.

The notes lack principal protection and expose holders to two uncorrelated risks: (1) a single-stock 40 % downside tranche and (2) UBS default probability. FINMA’s broad bail-in powers heighten recovery uncertainty. The unlisted nature of the security could magnify mark-to-market losses if volatility spikes. Investors pay $30 above fair value (issue vs. model), plus contingent tax and withholding complexities. From a portfolio-wide VaR perspective, concentration in a single health-care mega-cap is sub-optimal for most diversified mandates.

UBS AG Filiale di Londra offre un ammontare principale di $710.000 di Trigger Autocallable Contingent Yield Notes collegati alle azioni ordinarie di UnitedHealth Group Inc. (UNH), con scadenza il 13 luglio 2028. Ogni nota da $1.000 paga un coupon trimestrale contingente del 13,85% annuo ($34,625 per periodo) solo se il prezzo di chiusura di UNH in una data di osservazione è pari o superiore alla Barriera del Coupon / Soglia di ribasso di $179,71 (60% del livello iniziale di $299,51).

A partire da sei mesi dopo l’emissione, le note saranno richiamate automaticamente se UNH chiude pari o superiore alla Soglia di Richiamo ($299,51, 100% del livello iniziale) in una qualsiasi data di osservazione trimestrale. Il rimborso anticipato prevede il pagamento del capitale più il coupon dovuto e termina l’investimento.

Se non richiamate, il pagamento a scadenza dipende dal livello finale:

  • ≥ $179,71 (≥ 60%): restituzione del capitale (e ultimo coupon, se barriera rispettata).
  • < $179,71: gli investitori ricevono $1.000 × (1 + Rendimento Sottostante), subendo la perdita percentuale completa di UNH sotto il livello iniziale, fino alla perdita totale del capitale.
Tutti i pagamenti sono obbligazioni generali non garantite di UBS AG; coupon e protezione del capitale sono condizionati.

Termini economici chiave:

  • Prezzo di emissione: $1.000; valore iniziale stimato: $970 (riflette spread del dealer, costi di finanziamento e copertura).
  • Sconto di sottoscrizione: $23,50 (2,35%) per nota; proventi netti per UBS: $976,50.
  • Data di negoziazione: 10 lug 2025; regolamento: 15 lug 2025; date di osservazione trimestrali; primo possibile regolamento di richiamo: 15 gen 2026.
  • Le note non saranno quotate; UBS Securities LLC intende – ma non è obbligata – a fornire mercati secondari.

Rischi principali includono:

  • Perdita fino al 100% del capitale se UNH scende oltre il 40% alla valutazione finale.
  • Nessun coupon se UNH resta sotto la barriera del 60% nelle date di osservazione.
  • Esposizione creditizia a UBS AG; i pagamenti dipendono dalla solvibilità dell’emittente.
  • Valore stimato inferiore al prezzo di emissione e potenziali ampi spread denaro-lettera.
  • Liquidità limitata; gli investitori potrebbero dover mantenere fino a scadenza o accettare uno sconto.

Le note possono interessare investitori in cerca di un elevato reddito contingente disposti ad accettare un rischio di ribasso simile a quello azionario e il rischio di credito dell’emittente, rinunciando a qualsiasi rialzo oltre i coupon e affrontando la possibile richiamata anticipata.

UBS AG Sucursal de Londres ofrece un monto principal de $710,000 en Trigger Autocallable Contingent Yield Notes vinculados a las acciones ordinarias de UnitedHealth Group Inc. (UNH), con vencimiento el 13 de julio de 2028. Cada nota de $1,000 paga un cupón trimestral contingente del 13.85% anual ($34.625 por período) solo cuando el precio de cierre de UNH en una fecha de observación está en o por encima de la Barrera de Cupón / Umbral de Caída de $179.71 (60% del nivel inicial de $299.51).

A partir de seis meses después de la emisión, las notas serán llamadas automáticamente si UNH cierra en o por encima del Umbral de Llamado ($299.51, 100% del nivel inicial) en cualquier fecha de observación trimestral. El rescate anticipado paga el principal más el cupón correspondiente y termina la inversión.

Si no se llaman, el pago al vencimiento depende del nivel final:

  • ≥ $179.71 (≥ 60%): devolución del principal (y cupón final, si se cumple la barrera).
  • < $179.71: los inversores reciben $1,000 × (1 + Rendimiento Subyacente), asumiendo la pérdida porcentual total de UNH por debajo del nivel inicial, hasta una pérdida total del principal.
Todos los pagos son obligaciones generales no garantizadas de UBS AG; el cupón y la protección del principal son condicionales.

Términos económicos clave:

  • Precio de emisión: $1,000; valor inicial estimado: $970 (refleja spread del distribuidor, costos de financiamiento y cobertura).
  • Descuento de suscripción: $23.50 (2.35%) por nota; ingresos netos para UBS: $976.50.
  • Fecha de negociación: 10 jul 2025; liquidación: 15 jul 2025; fechas de observación trimestrales; primer posible pago por llamado: 15 ene 2026.
  • Las notas no estarán listadas; UBS Securities LLC tiene la intención —pero no está obligado— de proporcionar mercados secundarios.

Riesgos principales incluyen:

  • Pérdida de hasta el 100% del principal si UNH cae más del 40% en la valoración final.
  • No hay cupones si UNH permanece por debajo de la barrera del 60% en las fechas de observación.
  • Exposición crediticia a UBS AG; los pagos dependen de la solvencia del emisor.
  • Valor estimado por debajo del precio de emisión y posibles amplios spreads de compra/venta.
  • Liquidez limitada; los inversores pueden necesitar mantener hasta el vencimiento o aceptar un descuento.

Las notas pueden atraer a inversores que buscan altos ingresos contingentes y están dispuestos a aceptar un riesgo a la baja similar al de acciones y riesgo crediticio del emisor, renunciando a cualquier ganancia más allá de los cupones y enfrentando posible rescate anticipado.

UBS AG 런던 지점UnitedHealth Group Inc. (UNH)의 보통주에 연계된 Trigger Autocallable Contingent Yield Notes 원금 $710,000을 제공하며, 만기는 2028년 7월 13일입니다. 각 $1,000 노트는 UNH의 종가가 관측일에 쿠폰 장벽/하락 한계 $179.71 (초기 수준 $299.51의 60%) 이상일 때만 분기별로 연 13.85%의 조건부 쿠폰(기간당 $34.625)을 지급합니다.

발행 6개월 후부터는 UNH가 분기별 관측일에 콜 임계값($299.51, 초기 수준의 100%) 이상으로 마감하면 노트가 자동으로 상환됩니다. 조기 상환 시 원금과 해당 쿠폰이 지급되며 투자는 종료됩니다.

콜되지 않을 경우 만기 지급액은 최종 수준에 따라 달라집니다:

  • ≥ $179.71 (≥ 60%): 원금 반환(장벽 충족 시 최종 쿠폰 포함).
  • < $179.71: 투자자는 $1,000 × (1 + 기초자산 수익률)를 받으며, 초기 수준 이하 UNH의 하락률만큼 전액 손실을 입을 수 있습니다.
모든 지급은 UBS AG의 일반 무담보 채무이며, 쿠폰과 원금 보호는 조건부입니다.

주요 경제 조건:

  • 발행가: $1,000; 추정 초기 가치: $970 (딜러 스프레드, 자금 조달 및 헤지 비용 반영).
  • 인수 할인: 노트당 $23.50 (2.35%); UBS 순수익: $976.50.
  • 거래일: 2025년 7월 10일; 결제일: 2025년 7월 15일; 분기별 관측일; 첫 조기 상환 가능 결제일: 2026년 1월 15일.
  • 노트는 상장되지 않음; UBS Securities LLC는 2차 시장 제공을 계획하지만 의무는 아님.

주요 위험은 다음과 같습니다:

  • UNH가 최종 평가 시 40% 이상 하락하면 원금 최대 100% 손실 가능.
  • 관측일에 UNH가 60% 장벽 아래에 있으면 쿠폰 미지급.
  • UBS AG에 대한 신용 노출; 지급은 발행자의 지급 능력에 달려 있음.
  • 발행가보다 낮은 추정 가치 및 넓은 매수/매도 스프레드 가능성.
  • 유동성 제한; 투자자는 만기까지 보유하거나 할인된 가격에 매도할 수 있음.

이 노트는 높은 조건부 수익을 추구하며 주식과 유사한 하방 위험과 발행자 신용 위험을 감수할 투자자에게 적합하며, 쿠폰 이상의 상승 이익을 포기하고 조기 상환 가능성에 직면할 수 있습니다.

UBS AG Succursale de Londres propose un montant principal de 710 000 $ en Trigger Autocallable Contingent Yield Notes liés aux actions ordinaires de UnitedHealth Group Inc. (UNH), arrivant à échéance le 13 juillet 2028. Chaque note de 1 000 $ verse un coupon trimestriel conditionnel de 13,85 % par an (34,625 $ par période) uniquement lorsque le cours de clôture de UNH à une date d’observation est égal ou supérieur à la barrière de coupon / seuil de baisse de 179,71 $ (60 % du niveau initial de 299,51 $).

À partir de six mois après l’émission, les notes seront appelées automatiquement si UNH clôture à ou au-dessus du seuil d’appel (299,51 $, 100 % du niveau initial) à une date d’observation trimestrielle. Le remboursement anticipé paie le principal plus le coupon dû et met fin à l’investissement.

Si elles ne sont pas appelées, le paiement à l’échéance dépend du niveau final :

  • ≥ 179,71 $ (≥ 60 %) : remboursement du principal (et coupon final si la barrière est atteinte).
  • < 179,71 $ : les investisseurs reçoivent 1 000 $ × (1 + rendement sous-jacent), subissant la perte en pourcentage complète de UNH sous le niveau initial, jusqu’à une perte totale du principal.
Tous les paiements sont des obligations générales non garanties de UBS AG ; le coupon et la protection du principal sont conditionnels.

Principaux termes économiques :

  • Prix d’émission : 1 000 $ ; valeur initiale estimée : 970 $ (intègre le spread du teneur de marché, les coûts de financement et de couverture).
  • Remise de souscription : 23,50 $ (2,35 %) par note ; produit net pour UBS : 976,50 $.
  • Date de transaction : 10 juillet 2025 ; règlement : 15 juillet 2025 ; dates d’observation trimestrielles ; premier règlement possible d’appel : 15 janvier 2026.
  • Les notes ne seront pas cotées ; UBS Securities LLC prévoit — mais n’est pas obligée — de fournir des marchés secondaires.

Principaux risques incluent :

  • Perte pouvant atteindre 100 % du principal si UNH chute de plus de 40 % à la valorisation finale.
  • Pas de coupons si UNH reste sous la barrière de 60 % aux dates d’observation.
  • Exposition au risque de crédit de UBS AG ; les paiements dépendent de la solvabilité de l’émetteur.
  • Valeur estimée inférieure au prix d’émission et spreads acheteur/vendeur potentiellement larges.
  • Liquidité limitée ; les investisseurs peuvent devoir conserver jusqu’à l’échéance ou accepter une décote.

Ces notes peuvent intéresser les investisseurs recherchant un revenu conditionnel élevé et prêts à accepter un risque de baisse similaire à celui des actions ainsi que le risque de crédit de l’émetteur, renonçant à tout potentiel de hausse au-delà des coupons et faisant face à un possible remboursement anticipé.

UBS AG London Niederlassung bietet eine Hauptsumme von $710.000 in Trigger Autocallable Contingent Yield Notes an, die an die Stammaktien von UnitedHealth Group Inc. (UNH) gekoppelt sind und am 13. Juli 2028 fällig werden. Jede $1.000 Note zahlt einen vierteljährlichen bedingten Kupon von 13,85% p.a. ($34,625 pro Periode), jedoch nur, wenn der Schlusskurs von UNH am Beobachtungstag auf oder über der Kupon-Schwelle / Downside-Schwelle von $179,71 (60 % des Anfangsniveaus von $299,51) liegt.

Ab sechs Monaten nach Ausgabe werden die Notes automatisch zurückgerufen, wenn UNH an einem vierteljährlichen Beobachtungstag auf oder über der Rückruf-Schwelle ($299,51, 100 % des Anfangsniveaus) schließt. Eine vorzeitige Rückzahlung zahlt den Kapitalbetrag plus den fälligen Kupon und beendet die Anlage.

Wird nicht zurückgerufen, hängt die Rückzahlung bei Fälligkeit vom Endniveau ab:

  • ≥ $179,71 (≥ 60 %): Rückzahlung des Kapitals (und finaler Kupon, falls Schwelle erfüllt).
  • < $179,71: Anleger erhalten $1.000 × (1 + Basisrendite), erleiden also den vollen prozentualen Verlust von UNH unter dem Anfangsniveau bis hin zum Totalverlust des Kapitals.
Alle Zahlungen sind unbesicherte allgemeine Verbindlichkeiten der UBS AG; Kupon und Kapitalschutz sind bedingt.

Wichtige wirtschaftliche Bedingungen:

  • Ausgabepreis: $1.000; geschätzter Anfangswert: $970 (berücksichtigt Händler-Spread, Finanzierung & Absicherungskosten).
  • Underwriting-Discount: $23,50 (2,35 %) pro Note; Nettoerlös für UBS: $976,50.
  • Handelstag: 10. Juli 2025; Abwicklung: 15. Juli 2025; vierteljährliche Beobachtungstermine; erster möglicher Rückzahlungszeitpunkt: 15. Januar 2026.
  • Die Notes werden nicht börsennotiert; UBS Securities LLC beabsichtigt – ist aber nicht verpflichtet – Sekundärmärkte bereitzustellen.

Hauptrisiken umfassen:

  • Verlust von bis zu 100 % des Kapitals, wenn UNH bei der Endbewertung um mehr als 40 % fällt.
  • Keine Kupons, wenn UNH an Beobachtungstagen unter der 60 %-Schwelle bleibt.
  • Kreditrisiko gegenüber UBS AG; Zahlungen hängen von der Solvenz des Emittenten ab.
  • Geschätzter Wert unter dem Ausgabepreis und potenziell breite Geld-/Briefspannen.
  • Begrenzte Liquidität; Anleger müssen möglicherweise bis zur Fälligkeit halten oder Abschläge akzeptieren.

Die Notes könnten für Anleger attraktiv sein, die ein hohes bedingtes Einkommen suchen und bereit sind, ein aktienähnliches Abwärtsrisiko sowie Emittenten-Kreditrisiko zu akzeptieren, dabei auf Kursgewinne über die Kupons hinaus verzichten und eine mögliche vorzeitige Rückzahlung in Kauf nehmen.

The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not
an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion dated July 14, 2025
July , 2025 Registration Statement Nos. 333-270004 and 333-270004-01; Rule 424(b)(2)
Pricing supplement to product supplement no. 4-I dated April 13, 2023, underlying supplement no. 1-I dated April 13, 2023,
the prospectus and prospectus supplement, each dated April 13, 2023, and the prospectus addendum dated June 3, 2024
JPMorgan Chase Financial Company LLC
Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the
Least Performing of the iShares® Russell 2000 ETF, the
SPDR® Dow Jones Industrial AverageSM ETF Trust and the
SPDR® S&P 500® ETF Trust due July 30, 2030
Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.
The notes are designed for investors who seek uncapped, unleveraged exposure to any appreciation of the least
performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones Industrial AverageSM ETF Trust and the SPDR®
S&P 500® ETF Trust, which we refer to as the Funds, at maturity, subject to a contingent minimum return of at least
58.25%, which we refer to as the Contingent Digital Return.
The notes are also designed for investors who seek a capped, unleveraged return equal to the absolute value of any
depreciation of the least performing Fund at maturity (up to 30.00%) if the Final Value of each Fund is greater than or
equal to 70.00% of its Initial Value, which we refer to as a Barrier Amount.
Investors should be willing to forgo interest and dividend payments and be willing to lose a significant portion or all of
their principal amount at maturity.
The notes are unsecured and unsubordinated obligations of JPMorgan Chase Financial Company LLC, which we refer to
as JPMorgan Financial, the payment on which is fully and unconditionally guaranteed by JPMorgan Chase & Co. Any
payment on the notes is subject to the credit risk of JPMorgan Financial, as issuer of the notes, and the credit
risk of JPMorgan Chase & Co., as guarantor of the notes.
Payments on the notes are not linked to a basket composed of the Funds. Payments on the notes are linked to the
performance of each of the Funds individually, as described below.
Minimum denominations of $1,000 and integral multiples thereof
The notes are expected to price on or about July 25, 2025 and are expected to settle on or about July 30, 2025.
CUSIP: 48136FUC4
Investing in the notes involves a number of risks. See “Risk Factors” beginning on page S-2 of the accompanying
prospectus supplement, Annex A to the accompanying prospectus addendum, “Risk Factors” beginning on page PS-11
of the accompanying product supplement and “Selected Risk Considerations” beginning on page PS-4 of this pricing
supplement.
Neither the Securities and Exchange Commission (the SEC) nor any state securities commission has approved or disapproved
of the notes or passed upon the accuracy or the adequacy of this pricing supplement or the accompanying product supplement,
underlying supplement, prospectus supplement, prospectus and prospectus addendum. Any representation to the contrary is a
criminal offense.
Price to Public (1)
Fees and Commissions (2)
Proceeds to Issuer
Per note
$1,000
$
$
Total
$
$
$
(1) See Supplemental Use of Proceeds in this pricing supplement for information about the components of the price to public of the
notes.
(2) J.P. Morgan Securities LLC, which we refer to as JPMS, acting as agent for JPMorgan Financial, will pay all of the selling
commissions it receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed $2.00 per
$1,000 principal amount note. See Plan of Distribution (Conflicts of Interest) in the accompanying product supplement.
If the notes priced today, the estimated value of the notes would be approximately $981.70 per $1,000 principal amount
note. The estimated value of the notes, when the terms of the notes are set, will be provided in the pricing supplement
and will not be less than $970.00 per $1,000 principal amount note. See The Estimated Value of the Notes in this
pricing supplement for additional information.
The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency
and are not obligations of, or guaranteed by, a bank.
PS-1 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
Key Terms
Issuer: JPMorgan Chase Financial Company LLC, a direct,
wholly owned finance subsidiary of JPMorgan Chase & Co.
Guarantor: JPMorgan Chase & Co.
Funds: The iShares® Russell 2000 ETF (Bloomberg ticker:
IWM), the SPDR® Dow Jones Industrial AverageSM ETF Trust
(Bloomberg ticker: DIA) and the SPDR® S&P 500® ETF Trust
(Bloomberg Ticker: SPY)
Contingent Digital Return: At least 58.25% (to be provided in
the pricing supplement)
Barrier Amount: With respect to each Fund, 70.00% of its
Initial Value
Pricing Date: On or about July 25, 2025
Original Issue Date (Settlement Date): On or about July 30,
2025
Observation Date*: July 25, 2030
Maturity Date*: July 30, 2030
* Subject to postponement in the event of a market disruption event
and as described under General Terms of Notes Postponement
of a Determination Date Notes Linked to Multiple Underlyings
and General Terms of Notes Postponement of a Payment Date
in the accompanying product supplement
Payment at Maturity:
If the Final Value of each Fund is greater than or equal to its
Initial Value, your payment at maturity per $1,000 principal
amount note will be calculated as follows:
$1,000 + ($1,000 × greater of (a) Contingent Digital Return and
(b) Least Performing Fund Return)
If the Final Value of any Fund is less than its Initial Value but
the Final Value of each Fund is greater than or equal to its
Barrier Amount, your payment at maturity per $1,000 principal
amount note will be calculated as follows:
$1,000 + ($1,000 × Absolute Fund Return of the Least
Performing Fund)
This payout formula results in an effective cap of 30.00% on
your return at maturity if the Least Performing Fund Return is
negative. Under these limited circumstances, your maximum
payment at maturity is $1,300.00 per $1,000 principal amount
note.
If the Final Value of any Fund is less than its Barrier Amount,
your payment at maturity per $1,000 principal amount note will
be calculated as follows:
$1,000 + ($1,000 × Least Performing Fund Return)
If the Final Value of any Fund is less than its Barrier Amount,
you will lose more than 30.00% of your principal amount at
maturity and could lose all of your principal amount at maturity.
Absolute Fund Return: With respect to each Fund, the
absolute value of its Fund Return. For example, if the Fund
Return of a Fund is -5%, its Absolute Fund Return will equal
5%.
Least Performing Fund: The Fund with the Least Performing
Fund Return
Least Performing Fund Return: The lowest of the Fund
Returns of the Funds
Fund Return:
With respect to each Fund,
(Final Value Initial Value)
Initial Value
Initial Value: With respect to each Fund, the closing price of
one share of that Fund on the Pricing Date
Final Value: With respect to each Fund, the closing price of
one share of that Fund on the Observation Date
Share Adjustment Factor: With respect to each Fund, the
Share Adjustment Factor is referenced in determining the
closing price of one share of that Fund and is set equal to 1.0
on the Pricing Date. The Share Adjustment Factor of each
Fund is subject to adjustment upon the occurrence of certain
events affecting that Fund. See “The Underlyings — Funds
Anti-Dilution Adjustments” in the accompanying product
supplement for further information.
PS-2 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
Supplemental Terms of the Notes
Any values of the Funds, and any values derived therefrom, included in this pricing supplement may be corrected, in the event of
manifest error or inconsistency, by amendment of this pricing supplement and the corresponding terms of the notes. Notwithstanding
anything to the contrary in the indenture governing the notes, that amendment will become effective without consent of the holders of
the notes or any other party.
Hypothetical Payout Profile
The following table and graph illustrate the hypothetical total return and payment at maturity on the notes linked to three hypothetical
Funds. The total return as used in this pricing supplement is the number, expressed as a percentage, that results from comparing the
payment at maturity per $1,000 principal amount note to $1,000. The hypothetical total returns and payments set forth below assume
the following:
an Initial Value for the Least Performing Fund of $100.00;
a Contingent Digital Return of 58.25%; and
a Barrier Amount for the Least Performing Fund of $70.00 (equal to 70.00% of its hypothetical Initial Value).
The hypothetical Initial Value of the Least Performing Fund of $100.00 has been chosen for illustrative purposes only and may not
represent a likely actual Initial Value of any Fund. The actual Initial Value of each Fund will be the closing price of one share of that
Fund on the Pricing Date and will be provided in the pricing supplement. For historical data regarding the actual closing prices of one
share of each Fund, please see the historical information set forth under The Funds in this pricing supplement.
Each hypothetical total return or hypothetical payment at maturity set forth below is for illustrative purposes only and may not be the
actual total return or payment at maturity applicable to a purchaser of the notes. The numbers appearing in the following table and
graph have been rounded for ease of analysis.
Final Value of the
Least Performing Fund
Least Performing
Fund Return
Absolute Fund Return
of the Least
Performing Fund
Total Return on the
Notes
Payment at Maturity
$200.00
100.00%
N/A
100.00%
$2,000.00
$180.00
80.00%
N/A
80.00%
$1,800.00
$165.00
65.00%
N/A
65.00%
$1,650.00
$158.25
58.25%
N/A
58.25%
$1,582.50
$150.00
50.00%
N/A
58.25%
$1,582.50
$140.00
40.00%
N/A
58.25%
$1,582.50
$130.00
30.00%
N/A
58.25%
$1,582.50
$120.00
20.00%
N/A
58.25%
$1,582.50
$110.00
10.00%
N/A
58.25%
$1,582.50
$105.00
5.00%
N/A
58.25%
$1,582.50
$101.00
1.00%
N/A
58.25%
$1,582.50
$100.00
0.00%
N/A
58.25%
$1,582.50
$95.00
-5.00%
5.00%
5.00%
$1,050.00
$90.00
-10.00%
10.00%
10.00%
$1,100.00
$80.00
-20.00%
20.00%
20.00%
$1,200.00
$70.00
-30.00%
30.00%
30.00%
$1,300.00
$69.99
-30.01%
N/A
-30.01%
$699.90
$60.00
-40.00%
N/A
-40.00%
$600.00
$50.00
-50.00%
N/A
-50.00%
$500.00
$40.00
-60.00%
N/A
-60.00%
$400.00
$30.00
-70.00%
N/A
-70.00%
$300.00
$20.00
-80.00%
N/A
-80.00%
$200.00
$10.00
-90.00%
N/A
-90.00%
$100.00
$0.00
-100.00%
N/A
-100.00%
$0.00
PS-3 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
The following graph demonstrates the hypothetical payments at maturity on the notes for a range of Least Performing Fund Returns.
There can be no assurance that the performance of the Least Performing Fund will result in the return of any of your principal amount.
How the Notes Work
Least Performing Fund Par or Least Performing Fund Appreciation Upside Scenario:
If the Final Value of each Fund is greater than or equal to its Initial Value, investors will receive at maturity the $1,000 principal amount
plus a return equal to the greater of (a) the Contingent Digital Return of at least 58.25% and (b) the Least Performing Fund Return.
Assuming a hypothetical Contingent Digital Return of 58.25%, if the closing price of one share of the Least Performing Fund
increases 10.00%, investors will receive at maturity a return equal to 58.25%, or $1,582.50 per $1,000 principal amount note.
Assuming a hypothetical Contingent Digital Return of 58.25%, if the closing price of one share of the Least Performing Fund
increases 80.00%, investors will receive at maturity a return equal to 80.00%, or $1,800.00 per $1,000 principal amount note.
Least Performing Fund Depreciation Upside Scenario:
If the Final Value of any Fund is less than its Initial Value but the Final Value of each Fund is greater than or equal to its Barrier Amount
of 70.00% of its Initial Value, investors will receive at maturity the $1,000 principal amount plus a return equal to the Absolute Fund
Return of the Least Performing Fund.
For example, if the closing price of one share of the Least Performing Fund declines 10.00%, investors will receive at maturity a
10.00% return, or $1,100.00 per $1,000 principal amount note.
Downside Scenario:
If the Final Value of any Fund is less than its Barrier Amount of 70.00% of its Initial Value, investors will lose 1% of the principal amount
of their notes for every 1% that the Final Value of the Least Performing Fund is less than its Initial Value.
For example, if the closing price of one share of the Least Performing Fund declines 60.00%, investors will lose 60.00% of their
principal amount and receive only $400.00 per $1,000 principal amount note at maturity.
The hypothetical returns and hypothetical payments on the notes shown above apply only if you hold the notes for their entire term.
These hypotheticals do not reflect the fees or expenses that would be associated with any sale in the secondary market. If these fees
and expenses were included, the hypothetical returns and hypothetical payments shown above would likely be lower.
PS-4 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
Selected Risk Considerations
An investment in the notes involves significant risks. These risks are explained in more detail in the Risk Factors sections of the
accompanying prospectus supplement and product supplement and in Annex A to the accompanying prospectus addendum.
Risks Relating to the Notes Generally
YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS
The notes do not guarantee any return of principal. If the Final Value of any Fund is less than its Barrier Amount, you will lose 1%
of the principal amount of your notes for every 1% that the Final Value of the Least Performing Fund is less than its Initial Value.
Accordingly, under these circumstances, you will lose more than 30.00% of your principal amount at maturity and could lose all of
your principal amount at maturity.
YOUR ABILITY TO RECEIVE THE CONTINGENT DIGITAL RETURN MAY TERMINATE ON THE OBSERVATION DATE
If the Final Value of any Fund is less than its Initial Value, you will not be entitled to receive the Contingent Digital Return at
maturity.
YOUR MAXIMUM GAIN ON THE NOTES IS LIMITED BY THE BARRIER AMOUNT IF THE LEAST PERFORMING FUND
RETURN IS NEGATIVE
Because the payment at maturity will not reflect the Absolute Fund Return of the Least Performing Fund if its Final Value is less
than its Barrier Amount, the Barrier Amount effectively caps your return at maturity if the Least Performing Fund Return is negative.
The maximum payment at maturity if the Least Performing Fund Return is negative is $1,300.00 per $1,000 principal amount note.
CREDIT RISKS OF JPMORGAN FINANCIAL AND JPMORGAN CHASE & CO.
Investors are dependent on our and JPMorgan Chase & Co.s ability to pay all amounts due on the notes. Any actual or potential
change in our or JPMorgan Chase & Co.s creditworthiness or credit spreads, as determined by the market for taking that credit
risk, is likely to adversely affect the value of the notes. If we and JPMorgan Chase & Co. were to default on our payment
obligations, you may not receive any amounts owed to you under the notes and you could lose your entire investment.
AS A FINANCE SUBSIDIARY, JPMORGAN FINANCIAL HAS NO INDEPENDENT OPERATIONS AND HAS LIMITED ASSETS
As a finance subsidiary of JPMorgan Chase & Co., we have no independent operations beyond the issuance and administration of
our securities and the collection of intercompany obligations. Aside from the initial capital contribution from JPMorgan Chase &
Co., substantially all of our assets relate to obligations of JPMorgan Chase & Co. to make payments under loans made by us to
JPMorgan Chase & Co. or under other intercompany agreements. As a result, we are dependent upon payments from JPMorgan
Chase & Co. to meet our obligations under the notes. We are not a key operating subsidiary of JPMorgan Chase & Co. and in a
bankruptcy or resolution of JPMorgan Chase & Co. we are not expected to have sufficient resources to meet our obligations in
respect of the notes as they come due. If JPMorgan Chase & Co. does not make payments to us and we are unable to make
payments on the notes, you may have to seek payment under the related guarantee by JPMorgan Chase & Co., and that
guarantee will rank pari passu with all other unsecured and unsubordinated obligations of JPMorgan Chase & Co. For more
information, see the accompanying prospectus addendum.
YOU ARE EXPOSED TO THE RISK OF DECLINE IN THE PRICE OF ONE SHARE OF EACH FUND
Payments on the notes are not linked to a basket composed of the Funds and are contingent upon the performance of each
individual Fund. Poor performance by any of the Funds over the term of the notes may negatively affect your payment at maturity
and will not be offset or mitigated by positive performance by any other Fund.
YOUR PAYMENT AT MATURITY WILL BE DETERMINED BY THE LEAST PERFORMING FUND.
THE BENEFIT PROVIDED BY THE BARRIER AMOUNT MAY TERMINATE ON THE OBSERVATION DATE
If the Final Value of any Fund is less than its Barrier Amount, the benefit provided by the Barrier Amount will terminate and you will
be fully exposed to any depreciation of the Least Performing Fund.
THE NOTES DO NOT PAY INTEREST.
YOU WILL NOT RECEIVE DIVIDENDS ON ANY FUND OR THE SECURITIES HELD BY ANY FUND OR HAVE ANY RIGHTS
WITH RESPECT TO THE FUNDS OR THOSE SECURITIES.
PS-5 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
THE RISK OF THE CLOSING PRICE OF ONE SHARE OF A FUND FALLING BELOW ITS BARRIER AMOUNT IS GREATER IF
THE PRICE OF ONE SHARE OF THAT FUND IS VOLATILE.
LACK OF LIQUIDITY
The notes will not be listed on any securities exchange. Accordingly, the price at which you may be able to trade your notes is
likely to depend on the price, if any, at which JPMS is willing to buy the notes. You may not be able to sell your notes. The notes
are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity.
THE FINAL TERMS AND VALUATION OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT
You should consider your potential investment in the notes based on the minimums for the estimated value of the notes and the
Contingent Digital Return.
Risks Relating to Conflicts of Interest
POTENTIAL CONFLICTS
We and our affiliates play a variety of roles in connection with the notes. In performing these duties, our and JPMorgan Chase &
Co.s economic interests are potentially adverse to your interests as an investor in the notes. It is possible that hedging or trading
activities of ours or our affiliates in connection with the notes could result in substantial returns for us or our affiliates while the
value of the notes declines. Please refer to Risk Factors Risks Relating to Conflicts of Interest in the accompanying product
supplement.
Risks Relating to the Estimated Value and Secondary Market Prices of the Notes
THE ESTIMATED VALUE OF THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC) OF
THE NOTES
The estimated value of the notes is only an estimate determined by reference to several factors. The original issue price of the
notes will exceed the estimated value of the notes because costs associated with selling, structuring and hedging the notes are
included in the original issue price of the notes. These costs include the selling commissions, the projected profits, if any, that our
affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes and the estimated cost of hedging
our obligations under the notes. See The Estimated Value of the Notes in this pricing supplement.
THE ESTIMATED VALUE OF THE NOTES DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER
FROM OTHERS ESTIMATES
See The Estimated Value of the Notes in this pricing supplement.
THE ESTIMATED VALUE OF THE NOTES IS DERIVED BY REFERENCE TO AN INTERNAL FUNDING RATE
The internal funding rate used in the determination of the estimated value of the notes may differ from the market-implied funding
rate for vanilla fixed income instruments of a similar maturity issued by JPMorgan Chase & Co. or its affiliates. Any difference may
be based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance,
operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed income
instruments of JPMorgan Chase & Co. This internal funding rate is based on certain market inputs and assumptions, which may
prove to be incorrect, and is intended to approximate the prevailing market replacement funding rate for the notes. The use of an
internal funding rate and any potential changes to that rate may have an adverse effect on the terms of the notes and any
secondary market prices of the notes. See “The Estimated Value of the Notes” in this pricing supplement.
THE VALUE OF THE NOTES AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT
STATEMENTS) MAY BE HIGHER THAN THE THEN-CURRENT ESTIMATED VALUE OF THE NOTES FOR A LIMITED TIME
PERIOD
We generally expect that some of the costs included in the original issue price of the notes will be partially paid back to you in
connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period.
See Secondary Market Prices of the Notes in this pricing supplement for additional information relating to this initial period.
Accordingly, the estimated value of your notes during this initial period may be lower than the value of the notes as published by
JPMS (and which may be shown on your customer account statements).
PS-6 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
SECONDARY MARKET PRICES OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE
NOTES
Any secondary market prices of the notes will likely be lower than the original issue price of the notes because, among other
things, secondary market prices take into account our internal secondary market funding rates for structured debt issuances and,
also, because secondary market prices may exclude selling commissions, projected hedging profits, if any, and estimated hedging
costs that are included in the original issue price of the notes. As a result, the price, if any, at which JPMS will be willing to buy the
notes from you in secondary market transactions, if at all, is likely to be lower than the original issue price. Any sale by you prior to
the Maturity Date could result in a substantial loss to you.
SECONDARY MARKET PRICES OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS
The secondary market price of the notes during their term will be impacted by a number of economic and market factors, which
may either offset or magnify each other, aside from the selling commissions, projected hedging profits, if any, estimated hedging
costs and the prices of one share of the Funds. Additionally, independent pricing vendors and/or third party broker-dealers may
publish a price for the notes, which may also be reflected on customer account statements. This price may be different (higher or
lower) than the price of the notes, if any, at which JPMS may be willing to purchase your notes in the secondary market. See Risk
Factors Risks Relating to the Estimated Value and Secondary Market Prices of the Notes Secondary market prices of the
notes will be impacted by many economic and market factors in the accompanying product supplement.
Risks Relating to the Funds
JPMORGAN CHASE & CO. IS CURRENTLY ONE OF THE COMPANIES THAT MAKE UP THE SPDR® DOW JONES
INDUSTRIAL AVERAGESM ETF TRUST, THE SPDR® S&P 500® ETF TRUST AND THEIR UNDERLYING INDICES,
but JPMorgan Chase & Co. will not have any obligation to consider your interests in taking any corporate action that might affect
the price of one share of the SPDR® Dow Jones Industrial AverageSM ETF Trust or the SPDR® S&P 500® ETF Trust or the level of
either of their Underlying Indices (as defined under “The Funds” below).
THERE ARE RISKS ASSOCIATED WITH THE FUNDS
The Funds are subject to management risk, which is the risk that the investment strategies of the applicable Funds investment
adviser, the implementation of which is subject to a number of constraints, may not produce the intended results. These
constraints could adversely affect the market prices of the shares of the Funds and, consequently, the value of the notes.
THE PERFORMANCE AND MARKET VALUE OF EACH FUND, PARTICULARLY DURING PERIODS OF MARKET
VOLATILITY, MAY NOT CORRELATE WITH THE PERFORMANCE OF THAT FUNDS UNDERLYING INDEX AS WELL AS
THE NET ASSET VALUE PER SHARE
Each Fund does not fully replicate its Underlying Index (as defined under The Funds below) and may hold securities different
from those included in its Underlying Index. In addition, the performance of each Fund will reflect additional transaction costs and
fees that are not included in the calculation of its Underlying Index. All of these factors may lead to a lack of correlation between
the performance of each Fund and its Underlying Index. In addition, corporate actions with respect to the equity securities
underlying a Fund (such as mergers and spin-offs) may impact the variance between the performances of that Fund and its
Underlying Index. Finally, because the shares of each Fund are traded on a securities exchange and are subject to market supply
and investor demand, the market value of one share of each Fund may differ from the net asset value per share of that Fund.
During periods of market volatility, securities underlying each Fund may be unavailable in the secondary market, market
participants may be unable to calculate accurately the net asset value per share of that Fund and the liquidity of that Fund may be
adversely affected. This kind of market volatility may also disrupt the ability of market participants to create and redeem shares of
a Fund. Further, market volatility may adversely affect, sometimes materially, the prices at which market participants are willing to
buy and sell shares of a Fund. As a result, under these circumstances, the market value of shares of a Fund may vary
substantially from the net asset value per share of that Fund. For all of the foregoing reasons, the performance of each Fund may
not correlate with the performance of its Underlying Index as well as the net asset value per share of that Fund, which could
materially and adversely affect the value of the notes in the secondary market and/or reduce any payment on the notes.
AN INVESTMENT IN THE NOTES IS SUBJECT TO RISKS ASSOCIATED WITH SMALL CAPITALIZATION STOCKS WITH
RESPECT TO THE iSHARES® RUSSELL 2000 ETF
Small capitalization companies may be less able to withstand adverse economic, market, trade and competitive conditions relative
to larger companies. Small capitalization companies are less likely to pay dividends on their stocks, and the presence of a
dividend payment could be a factor that limits downward stock price pressure under adverse market conditions.
PS-7 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
THE ANTI-DILUTION PROTECTION FOR THE FUNDS IS LIMITED
The calculation agent will make adjustments to the Share Adjustment Factor for each Fund for certain events affecting the shares
of that Fund. However, the calculation agent will not make an adjustment in response to all events that could affect the shares of
the Funds. If an event occurs that does not require the calculation agent to make an adjustment, the value of the notes may be
materially and adversely affected.
PS-8 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
The Funds
The iShares® Russell 2000 ETF is an exchange-traded fund of iShares® Trust, a registered investment company, that seeks to track the
investment results, before fees and expenses, of an index composed of small-capitalization U.S. equities, which we refer to as the
Underlying Index with respect to the iShares® Russell 2000 ETF. The Underlying Index with respect to the iShares® Russell 2000 ETF
is currently the Russell 2000® Index. The Russell 2000® Index is designed to track the performance of the small capitalization segment
of the U.S. equity market. For additional information about the iShares® Russell 2000 ETF, see “Fund Descriptions — The iShares®
ETFs” in the accompanying underlying supplement.
The SPDR® Dow Jones Industrial AverageSM ETF Trust is an exchange-traded fund that seeks to provide investment results that,
before expenses, generally correspond to the price and yield performance of the Dow Jones Industrial Average®, which we refer to as
the Underlying Index with respect to the SPDR® Dow Jones Industrial AverageSM ETF Trust. The Dow Jones Industrial Average®
consists of 30 common stocks chosen as representative of the broad market of U.S. industry. For additional information about the
SPDR® Dow Jones Industrial AverageSM ETF Trust, see “Fund Descriptions — The SPDR® Dow Jones Industrial AverageSM ETF Trust”
in the accompanying underlying supplement.
The SPDR® S&P 500® ETF Trust is a registered investment company whose trust units represent an undivided ownership interest in a
portfolio of all, or substantially all, of the common stocks of the S&P 500® Index. The SPDR® S&P 500® ETF Trust seeks to provide
investment results that, before expenses, generally correspond to the price and yield performance of the S&P 500® Index, which we
refer to as the Underlying Index with respect to the SPDR® S&P 500® ETF Trust. The S&P 500® Index consists of stocks of 500
companies selected to provide a performance benchmark for the U.S. equity markets. For additional information about the SPDR® S&P
500® ETF Trust, see “Fund Descriptions — The SPDR® S&P 500® ETF Trust” in the accompanying underlying supplement.
Historical Information
The following graphs set forth the historical performance of each Fund based on the weekly historical closing prices of one share of
each Fund from January 3, 2020 through July 3, 2025. The closing price of one share of the iShares® Russell 2000 ETF on July 10,
2025 was $224.80. The closing price of one share of the SPDR® Dow Jones Industrial AverageSM ETF Trust on July 10, 2025 was
$446.50. The closing price of one share of the SPDR® S&P 500® ETF Trust on July 10, 2025 was $625.82. We obtained the closing
prices above and below from the Bloomberg Professional® service (“Bloomberg”), without independent verification. The closing prices
above and below may have been adjusted by Bloomberg for actions taken by the Funds, such as stock splits.
The historical closing prices of one share of each Fund should not be taken as an indication of future performance, and no assurance
can be given as to the closing price of one share of any Fund on the Pricing Date or the Observation Date. There can be no assurance
that the performance of the Funds will result in the return of any of your principal amount.
PS-9 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
Tax Treatment
You should review carefully the section entitled “Material U.S. Federal Income Tax Consequences” in the accompanying product
supplement no. 4-I. The following discussion, when read in combination with that section, constitutes the full opinion of our special tax
counsel, Davis Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of notes.
Based on current market conditions, in the opinion of our special tax counsel it is reasonable to treat the notes as “open transactions”
that are not debt instruments for U.S. federal income tax purposes, as more fully described in “Material U.S. Federal Income Tax
ConsequencesTax Consequences to U.S. Holders—Notes Treated as Open Transactions That Are Not Debt Instruments” in the
accompanying product supplement. Assuming this treatment is respected, subject to the possible application of the “constructive
ownership” rules, the gain or loss on your notes should be treated as long-term capital gain or loss if you hold your notes for more than
a year, whether or not you are an initial purchaser of notes at the issue price. The notes could be treated as “constructive ownership
transactions” within the meaning of Section 1260 of the Code, in which case any gain recognized in respect of the notes that would
otherwise be long-term capital gain and that was in excess of the “net underlying long-term capital gain” (as defined in Section 1260)
would be treated as ordinary income, and a notional interest charge would apply as if that income had accrued for tax purposes at a
constant yield over your holding period for the notes. Our special tax counsel has not expressed an opinion with respect to whether the
constructive ownership rules apply to the notes. Accordingly, U.S. Holders should consult their tax advisers regarding the potential
application of the constructive ownership rules.
PS-10 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
The IRS or a court may not respect the treatment of the notes described above, in which case the timing and character of any income
or loss on your notes could be materially and adversely affected. In addition, in 2007 Treasury and the IRS released a notice
requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts” and similar instruments. The notice
focuses in particular on whether to require investors in these instruments to accrue income over the term of their investment. It also
asks for comments on a number of related topics, including the character of income or loss with respect to these instruments; the
relevance of factors such as the nature of the underlying property to which the instruments are linked; the degree, if any, to which
income (including any mandated accruals) realized by non-U.S. investors should be subject to withholding tax; and whether these
instruments are or should be subject to the constructive ownership regime described above. While the notice requests comments on
appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect. You
should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes, including the
potential application of the constructive ownership rules, possible alternative treatments and the issues presented by this notice.
Section 871(m) of the Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding
tax (unless an income tax treaty applies) on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain
financial instruments linked to U.S. equities or indices that include U.S. equities. Section 871(m) provides certain exceptions to this
withholding regime, including for instruments linked to certain broad-based indices that meet requirements set forth in the applicable
Treasury regulations. Additionally, a recent IRS notice excludes from the scope of Section 871(m) instruments issued prior to January
1, 2027 that do not have a delta of one with respect to underlying securities that could pay U.S.-source dividends for U.S. federal
income tax purposes (each an “Underlying Security”). Based on certain determinations made by us, we expect that Section 871(m) will
not apply to the notes with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with
this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including whether you
enter into other transactions with respect to an Underlying Security. If necessary, further information regarding the potential application
of Section 871(m) will be provided in the pricing supplement for the notes. You should consult your tax adviser regarding the potential
application of Section 871(m) to the notes.
The Estimated Value of the Notes
The estimated value of the notes set forth on the cover of this pricing supplement is equal to the sum of the values of the following
hypothetical components: (1) a fixed-income debt component with the same maturity as the notes, valued using the internal funding
rate described below, and (2) the derivative or derivatives underlying the economic terms of the notes. The estimated value of the
notes does not represent a minimum price at which JPMS would be willing to buy your notes in any secondary market (if any exists) at
any time. The internal funding rate used in the determination of the estimated value of the notes may differ from the market-implied
funding rate for vanilla fixed income instruments of a similar maturity issued by JPMorgan Chase & Co. or its affiliates. Any difference
may be based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance,
operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed income
instruments of JPMorgan Chase & Co. This internal funding rate is based on certain market inputs and assumptions, which may prove
to be incorrect, and is intended to approximate the prevailing market replacement funding rate for the notes. The use of an internal
funding rate and any potential changes to that rate may have an adverse effect on the terms of the notes and any secondary market
prices of the notes. For additional information, see “Selected Risk Considerations — Risks Relating to the Estimated Value and
Secondary Market Prices of the Notes The Estimated Value of the Notes Is Derived by Reference to an Internal Funding Rate” in this
pricing supplement.
The value of the derivative or derivatives underlying the economic terms of the notes is derived from internal pricing models of our
affiliates. These models are dependent on inputs such as the traded market prices of comparable derivative instruments and on
various other inputs, some of which are market-observable, and which can include volatility, dividend rates, interest rates and other
factors, as well as assumptions about future market events and/or environments. Accordingly, the estimated value of the notes is
determined when the terms of the notes are set based on market conditions and other relevant factors and assumptions existing at that
time.
The estimated value of the notes does not represent future values of the notes and may differ from others estimates. Different pricing
models and assumptions could provide valuations for the notes that are greater than or less than the estimated value of the notes. In
addition, market conditions and other relevant factors in the future may change, and any assumptions may prove to be incorrect. On
future dates, the value of the notes could change significantly based on, among other things, changes in market conditions, our or
JPMorgan Chase & Co.s creditworthiness, interest rate movements and other relevant factors, which may impact the price, if any, at
which JPMS would be willing to buy notes from you in secondary market transactions.
PS-11 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
The estimated value of the notes will be lower than the original issue price of the notes because costs associated with selling,
structuring and hedging the notes are included in the original issue price of the notes. These costs include the selling commissions
paid to JPMS and other affiliated or unaffiliated dealers, the projected profits, if any, that our affiliates expect to realize for assuming
risks inherent in hedging our obligations under the notes and the estimated cost of hedging our obligations under the notes. Because
hedging our obligations entails risk and may be influenced by market forces beyond our control, this hedging may result in a profit that
is more or less than expected, or it may result in a loss. A portion of the profits, if any, realized in hedging our obligations under the
notes may be allowed to other affiliated or unaffiliated dealers, and we or one or more of our affiliates will retain any remaining hedging
profits. See “Selected Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes The
Estimated Value of the Notes Will Be Lower Than the Original Issue Price (Price to Public) of the Notes” in this pricing supplement.
Secondary Market Prices of the Notes
For information about factors that will impact any secondary market prices of the notes, see “Risk Factors — Risks Relating to the
Estimated Value and Secondary Market Prices of the Notes Secondary market prices of the notes will be impacted by many
economic and market factors” in the accompanying product supplement. In addition, we generally expect that some of the costs
included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of your notes by
JPMS in an amount that will decline to zero over an initial predetermined period. These costs can include selling commissions,
projected hedging profits, if any, and, in some circumstances, estimated hedging costs and our internal secondary market funding rates
for structured debt issuances. This initial predetermined time period is intended to be the shorter of six months and one-half of the
stated term of the notes. The length of any such initial period reflects the structure of the notes, whether our affiliates expect to earn a
profit in connection with our hedging activities, the estimated costs of hedging the notes and when these costs are incurred, as
determined by our affiliates. See “Selected Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices
of the Notes The Value of the Notes as Published by JPMS (and Which May Be Reflected on Customer Account Statements) May
Be Higher Than the Then-Current Estimated Value of the Notes for a Limited Time Period” in this pricing supplement.
Supplemental Use of Proceeds
The notes are offered to meet investor demand for products that reflect the risk-return profile and market exposure provided by the
notes. See Hypothetical Payout Profile and How the Notes Work in this pricing supplement for an illustration of the risk-return profile
of the notes and The Funds in this pricing supplement for a description of the market exposure provided by the notes.
The original issue price of the notes is equal to the estimated value of the notes plus the selling commissions paid to JPMS and other
affiliated or unaffiliated dealers, plus (minus) the projected profits (losses) that our affiliates expect to realize for assuming risks inherent
in hedging our obligations under the notes, plus the estimated cost of hedging our obligations under the notes.
Additional Terms Specific to the Notes
You may revoke your offer to purchase the notes at any time prior to the time at which we accept such offer by notifying the applicable
agent. We reserve the right to change the terms of, or reject any offer to purchase, the notes prior to their issuance. In the event of any
changes to the terms of the notes, we will notify you and you will be asked to accept such changes in connection with your purchase.
You may also choose to reject such changes, in which case we may reject your offer to purchase.
You should read this pricing supplement together with the accompanying prospectus, as supplemented by the accompanying
prospectus supplement relating to our Series A medium-term notes of which these notes are a part, the accompanying prospectus
addendum and the more detailed information contained in the accompanying product supplement and the accompanying underlying
supplement. This pricing supplement, together with the documents listed below, contains the terms of the notes and supersedes all
other prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms,
correspondence, trade ideas, structures for implementation, sample structures, fact sheets, brochures or other educational materials of
ours. You should carefully consider, among other things, the matters set forth in the Risk Factors sections of the accompanying
prospectus supplement and the accompanying product supplement and in Annex A to the accompanying prospectus addendum, as the
notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and
other advisers before you invest in the notes.
PS-12 | Structured Investments
Uncapped Dual Directional Digital Barrier Notes Linked to the Least
Performing of the iShares® Russell 2000 ETF, the SPDR® Dow Jones
Industrial AverageSM ETF Trust and the SPDR® S&P 500® ETF Trust
You may access these documents on the SEC website at www.sec.gov as follows (or if such address has changed, by
reviewing our filings for the relevant date on the SEC website):
Product supplement no. 4-I dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000121390023029539/ea152803_424b2.pdf
Underlying supplement no. 1-I dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000121390023029543/ea151873_424b2.pdf
Prospectus supplement and prospectus, each dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000095010323005751/crt_dp192097-424b2.pdf
Prospectus addendum dated June 3, 2024:
http://www.sec.gov/Archives/edgar/data/1665650/000095010324007599/dp211753_424b3.htm
Our Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing
supplement, “we,” “us” and “our” refer to JPMorgan Financial.

FAQ

What coupon rate do the UBS Trigger Autocallable Notes linked to UNH pay?

The notes pay a 13.85 % per annum contingent coupon, or $34.625 per $1,000 note each quarter when conditions are met.

When can the notes be automatically called by UBS AG?

Starting six months after issuance, the notes are called if UNH’s closing price is ≥ $299.51 (100 % of the initial level) on any quarterly observation date.

What happens at maturity if UNH falls more than 40 %?

If the final level is below the $179.71 downside threshold, investors receive $1,000 × (1 + Underlying Return), leading to a proportional loss of principal up to 100 %.

Is the principal of these notes guaranteed?

No. Principal is only returned in full if UNH stays at or above the downside threshold; otherwise investors bear full equity downside below 60 % of the initial level.

Will the notes be listed on an exchange or ECN?

No. The notes will not be listed; any resale depends on dealer interest, and prices may be below par.

What is the estimated initial value versus the issue price?

UBS estimates the initial value at $970, reflecting fees and hedging costs, versus the $1,000 issue price.
Inverse VIX S/T Futs ETNs due Mar22,2045

NYSE:VYLD

VYLD Rankings

VYLD Latest News

VYLD Latest SEC Filings

VYLD Stock Data

4.00M
National Commercial Banks
NEW YORK